Shabutdinova O R, Dautov A R, Samkov A A, Kononenko A V, Sargaliev A F, Davletshin A R, Andresova P A, Zarbeeva K R, Torshkhoeva D A, Rakhmonkulov U A, Afanasyev A A
Bashkir state medical university.
Dagestan state medical university.
Probl Endokrinol (Mosk). 2023 Jun 30;69(3):68-82. doi: 10.14341/probl13197.
Overweight and obesity are a worldwide common problem and are diagnosed with a body mass index (BMI) value in the range of 25.0-29.9 kg/m2 and ≥30.0 kg/m2, respectively. Obese patients are at high risk of developing concomitant diseases, such as hypertension, type 2 diabetes mellitus (DM2), hyperlipidemia, stroke and even some types of cancer. In the Russian Federation in 2016, the proportion of overweight people was 62.0%, with obesity - 26.2%. The authors performed an electronic search in the PubMed information database. Two search elements were used: «Semaglutide» and «Obesity». The search included studies published from the date of foundation of the database to August 2022. The search was limited only to the results of clinical trials. The authors obtained 26 results, but only the studies of SUSTAIN, PIONEER (Peptide Innovation for Early Diabetes Treatment) and STEP were considered, since they were original, randomized, controlled clinical trials conducted before the approval of semaglutide for the treatment of DM2 and obesity.
超重和肥胖是一个全球性的常见问题，分别通过体重指数（BMI）值在25.0 - 29.9 kg/m²和≥30.0 kg/m²范围内来诊断。肥胖患者患伴发疾病的风险很高，如高血压、2型糖尿病（DM2）、高脂血症、中风甚至某些类型的癌症。2016年在俄罗斯联邦，超重人群的比例为62.0%，肥胖人群为26.2%。作者在PubMed信息数据库中进行了电子检索。使用了两个检索词：“司美格鲁肽”和“肥胖”。检索范围包括从数据库建立之日到2022年8月发表的研究。检索仅限于临床试验结果。作者获得了26个结果，但仅考虑了SUSTAIN、PIONEER（早期糖尿病治疗的肽创新）和STEP的研究，因为它们是在司美格鲁肽被批准用于治疗DM2和肥胖之前进行的原始、随机、对照临床试验。
